Coherus BioSciences, Inc.

NasdaqGM:CHRS Rapporto sulle azioni

Cap. di mercato: US$94.6m

Coherus BioSciences Gestione

Gestione criteri di controllo 3/4

Coherus BioSciences Il CEO è Denny Lanfear, nominato in Sep2010, e ha un mandato di 14.17 anni. la retribuzione annua totale è $ 5.90M, composta da 16.7% di stipendio e 83.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.99% delle azioni della società, per un valore di $ 937.64K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 3.3 anni.

Informazioni chiave

Denny Lanfear

Amministratore delegato

US$5.9m

Compenso totale

Percentuale dello stipendio del CEO16.7%
Mandato del CEO14.2yrs
Proprietà del CEO1.0%
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione3.3yrs

Aggiornamenti recenti sulla gestione

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Recent updates

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15
Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Coherus: Will Its Chinese Gambit Fail?

May 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Denny Lanfear rispetto agli utili di Coherus BioSciences?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$450k

Jun 30 2024n/an/a

-US$29m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$983k

-US$238m

Sep 30 2023n/an/a

-US$217m

Jun 30 2023n/an/a

-US$264m

Mar 31 2023n/an/a

-US$271m

Dec 31 2022US$7mUS$945k

-US$292m

Sep 30 2022n/an/a

-US$279m

Jun 30 2022n/an/a

-US$230m

Mar 31 2022n/an/a

-US$210m

Dec 31 2021US$9mUS$885k

-US$287m

Sep 30 2021n/an/a

-US$232m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$7mUS$857k

US$132m

Sep 30 2020n/an/a

US$162m

Jun 30 2020n/an/a

US$181m

Mar 31 2020n/an/a

US$145m

Dec 31 2019US$5mUS$751k

US$90m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$4mUS$702k

-US$209m

Sep 30 2018n/an/a

-US$196m

Jun 30 2018n/an/a

-US$196m

Mar 31 2018n/an/a

-US$208m

Dec 31 2017US$3mUS$656k

-US$238m

Compensazione vs Mercato: La retribuzione totale di Denny ($USD 5.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 652.28K ).

Compensazione vs guadagni: La retribuzione di Denny è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Denny Lanfear (69 yo)

14.2yrs

Mandato

US$5,897,924

Compensazione

Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Dennis Lanfear
Chairman14.2yrsUS$5.90m0.99%
$ 937.6k
Bryan McMichael
Former Interim CFO2.2yrsUS$1.07m0.023%
$ 21.7k
Paul Reider
Chief Commercial Officer3.8yrsUS$1.93m0.071%
$ 66.8k
Richard Hameister
Chief Technical Officer2.8yrsNessun datoNessun dato
Jami Taylor
Vice President of Investor Relationsno dataNessun datoNessun dato
Andy Rittenberg
Executive Vice President of General Counselless than a yearNessun datoNessun dato
Cheston Turbyfill
Vice President of Communicationsno dataNessun datoNessun dato
Scott Saywell
Executive Vice President of Corporate Development1.8yrsNessun datoNessun dato
Rebecca Sunshine
Chief Human Resources Officerno dataNessun datoNessun dato
Michael Chen
Senior Vice President of Commercial Analytics & Tradeno dataNessun datoNessun dato
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsNessun datoNessun dato
Rosh Dias
Chief Medical Officer2.7yrsNessun datoNessun dato

2.8yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di CHRS è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dennis Lanfear
Chairman14.2yrsUS$5.90m0.99%
$ 937.6k
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsNessun datoNessun dato
Mats Wahlstrom
Lead Independent Director12.8yrsUS$228.69k0.087%
$ 82.1k
Mark Stolper
Independent Director3.8yrsUS$198.69k0.0076%
$ 7.2k
Ali Satvat
Independent Director10.5yrsUS$65.00k0%
$ 0
Lee Newcomer
Independent Director2.8yrsUS$186.19k0%
$ 0
James Daly
Member of Strategic Advisory Board1.2yrsNessun datoNessun dato
Charles Newton
Independent Director2.5yrsUS$188.69k0%
$ 0
Jill O'Donnell-Tormey
Independent Director2.5yrsUS$183.69k0%
$ 0
Kimberly Tzoumakas
Independent Director4.3yrsUS$193.69k0%
$ 0
Carl Ware
Member of Scientific Advisory Board3.3yrsNessun datoNessun dato
Thomas Graeber
Member of Scientific Advisory Board3.3yrsNessun datoNessun dato

3.3yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CHRS sono considerati esperti (durata media dell'incarico 3.3 anni).